Introduction {#Sec1}
============

Levodopa-related motor complications occur in the majority of patients with Parkinson's disease (PD) after 5--10 years of treatment \[[@CR1]\]. The motor complications are attributed to progressive loss of striatal dopamine nerve terminals, the short half-life of levodopa, as well as variable gastric emptying and intestinal absorption leading to irregular plasma levodopa levels \[[@CR2], [@CR3]\].

In addition, patients manifest non-motor symptoms (e.g., cognitive deficits, sleep abnormalities, autonomic dysfunction), which can greatly impair a patient's autonomy, resulting in increasing caregiver support and reduced quality of life. The prevalence of non-motor symptoms increases with disease severity but varies among the different domains and is patient specific \[[@CR4], [@CR5]\]. Several studies reported a strong contribution of non-motor symptoms on quality of life, confirming their relevance as therapeutic targets \[[@CR4], [@CR6]--[@CR8]\].

Levodopa--carbidopa intestinal gel \[LCIG, Duodopa^®^, carbidopa levodopa enteral suspension in the USA (CLES, Duopa^®^), AbbVie Inc, North Chicago, IL, USA\] is continuously delivered via percutaneous endoscopic gastrojejunostomy (PEG-J) in patients with advanced PD who have motor fluctuations and dyskinesia not adequately managed by available orally administered anti-Parkinsonian medications. Continuous delivery by PEG-J reduces variability in plasma levels by avoiding the effects of erratic gastric emptying \[[@CR9]\]. This strategy reduces "off" time and improves quality of life in patients with advanced PD in a controlled setting \[[@CR6], [@CR10]--[@CR14]\]. Previous studies have reported extensively on the safety and efficacy of LCIG in controlled settings; however, there is a dearth of "real-life" data available on the use of LCIG in clinical practice. Further, these studies have typically included patients with advanced PD as well as long disease duration. The objective of this study was to assess the effect of LCIG treatment on activities of daily living, motor and non-motor symptoms, and quality of life in patients as they start presenting with motor complications.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Patients were eligible to participate in the study if they fulfilled the following criteria at baseline: patients were diagnosed with advanced, levodopa-responsive PD; patients' physicians chose to use LCIG to treat patients' PD in accordance with the local approved use before any decision was made to solicit a patient's participation in this study; patients had unchanged PD treatment for at least 4 weeks before the baseline visit; patients received four or more daily oral doses of PD medication; and patients had 2--4 h of "off" time or 2 h of non-troublesome or troublesome dyskinesia daily supported by a Unified Parkinson's Disease Rating Scale (UPDRS) total score in the best "on" state of at least 40 points at baseline \[[@CR15], [@CR16]\]. Patients were excluded if they had been treated with deep brain stimulation (DBS), used apomorphine pump, received LCIG treatment before the baseline visit, or had evidence for clinically relevant cognitive deficits, as defined by a score less than 24 on the mini-mental state examination.

Study Design and Treatment {#Sec4}
--------------------------

This prospective, post-marketing observational study was performed in an international, multicenter setting at 30 sites. There were five target visits: baseline; hospital discharge; and months 3, 6, and 12 after hospital discharge. A temporary naso-jejunal tube was used for LCIG administration to determine if the patient responded favorably to LCIG and to optimize the dose before treatment was initiated via PEG-J tube. LCIG was administered directly into the proximal small intestine through a jejunal extension tube using a portable infusion pump. Patients who chose not to continue LCIG treatment after the temporary naso-jejunal test phase as well as patients who discontinued LCIG treatment during the study had the option to continue the study in the standard-of-care group (orally and/or transdermally administered anti-Parkinson's disease medications that patients were taking prior to consideration for LCIG treatment). If, during the study, a patient chose to be treated with apomorphine pump or DBS, the patient was no longer eligible to continue in the study. This study was conducted in accordance with the principles of the Declaration of Helsinki of 1964, as revised in 2013, good clinical practice, and applicable local legal and regulatory requirements. All patients provided written informed consent.

Assessments {#Sec5}
-----------

### Effectiveness {#Sec6}

The primary endpoint was the change from baseline to final visit in a patient's impairment in activities of daily living as measured by UPDRS Part II (score range 0--52; a higher score indicates a greater impairment; measured during the best "on" time). Secondary endpoints included the change from baseline in activities of daily living at other time points; UPDRS Part III and IV scores (measured during the best "on" time), scores on the Parkinson's Disease Questionnaire-8 (PDQ-8) summary index (assessing quality of life; score normalized to a scale of 0--100, with a higher summary index indicating a greater impairment); and scores on the Non-Motor Symptoms Scale (NMSS) and subdomains, which assessed non-motor symptoms over the previous month (total NMSS score range 0--360, with a higher score indicating more severe symptoms).

### Safety {#Sec7}

Safety was assessed by adverse events (AEs) and product complaints. Investigators identified the severity and seriousness of AEs, and indicated their opinion of the relationship of the AE to LCIG (reasonable possibility or not).

### Statistical Analysis {#Sec8}

All statistical analyses were performed using SAS^®^ version 9.2 (SAS Institute, Inc., Cary, NC, USA). Significant changes from baseline in the LCIG group were assessed using two-sided *t* tests. "Final" endpoints included data from month 12 with the last observation carried forward for missing values. The standard-of-care treatment group was not powered for statistical analysis; as such, statistical comparisons were not made within the standard-of-care treatment group nor between the standard of care and LCIG treatment groups.

Results {#Sec9}
=======

Patients {#Sec10}
--------

Patient baseline characteristics are shown in Table [1](#Tab1){ref-type="table"}. The majority of patients in this study were male, and the average age was 70.4 (7.8) years. The average PD duration was 13.9 (5.4) years and the most common previous PD therapies were orally administered levodopa (100%) and dopamine agonists (94%).Table 1Baseline demographics and disease characteristicsParameter*n* = 64Mean (SD) age, years70.4 (7.8)Sex, *n* (%) Male39 (61) Female25 (39)Mean (SD) PD duration, years13.9 (5.4)Previous PD therapy, *n* (%) Orally administered levodopa64 (100) Orally administered dopamine agonist60 (94) COMT inhibitor45 (70) MAO-B inhibitor38 (59) Amantadine31 (48) Rotigotine25 (39) Apomorphine, sc12 (19)Mean (SD) UPDRS Part II total score^a^18.1 (8.0)Mean (SD) UPDRS Part III total score^a^36 (16.2)Mean (SD) UPDRS Part IV score^a^ Item 321.4 (1.1) Item 331.4 (1.3) Item 340.6 (0.9)Mean (SD) PDQ-8 summary index48.6 (16.2)Mean (SD) NMSS total score95.5 (54.5)*SD* standard deviation, *PD* Parkinson's disease, *COMT* catechol-O-methyltransferase, *MAO*-*B* monoamine oxidase-B, *sc* subcutaneous, *UPDRS* Unified Parkinson's Disease Rating Scale, *PDQ*-*8* Parkinson's Disease Questionnaire-8 item, *NMSS* Non-Motor Symptoms Scale^a^UPDRS was measured during patients' best "on" time

Overall, 65 patients were screened and 64 patients began treatment via naso-jejunal tube (Fig. [1](#Fig1){ref-type="fig"}). One patient was excluded because of a protocol violation. A total of 58 (89%) continued to LCIG treatment via PEG-J after the initial naso-jejunal test phase. Six (9%) patients returned to the standard-of-care group after starting LCIG therapy via a naso-jejunal tube and prior to PEG-J placement (please see Supplemental Table 1 for detailed patient disposition by visit).Fig. 1Patient disposition from enrollment to day 1 post PEG-J placement. *LCIG* levodopa--carbidopa intestinal gel, *PEG*-*J* percutaneous endoscopic gastrojejunostomy

The mean (SD) study duration was 308 (129) days (range 1--546 days); the mean (SD) LCIG treatment duration was 275 (157) days (range 2--545 days). Forty-one patients (63%) completed all 12 months of LCIG treatment. Over the course of the study, 16 patients (25%) switched to the standard-of-care group (orally and/or transdermally administered dopaminergic therapy), although only six remained in the standard-of-care group through month 12. Of patients who did not remain in the standard-of-care group, one patient opted for an excluded surgical treatment and nine patients discontinued participation in the study (or there was no treatment information).

A total of 23 patients (35.9%) discontinued LCIG treatment during the study, most commonly by patients' decision (nine patients, 14.1%), or by the investigator as a result of a medical event (eight patients, 12.5%) (please see Supplemental Table 2 for reasons for discontinuation).

Effectiveness {#Sec11}
-------------

### LCIG Treatment Group {#Sec12}

In patients receiving LCIG, there was a significant improvement from baseline in patients' abilities to perform activities of daily living (UPDRS Part II) at the final visit \[mean (SD) change from baseline of −2.1 (6.9); *p* \< 0.05\] (Fig. [2](#Fig2){ref-type="fig"}). Results were also significant at months 3 and 6 (*p* \< 0.0001); an improvement of −1.8 (7.1) from baseline at month 12 was not significant.Fig. 2Mean (SD) change from baseline in measures of activities of daily living in the LCIG treatment group. Activities of daily living were measured by UPDRS Part II total score during the best "on" time. Statistical significance compared with baseline is indicated at *p* ≤ 0.05 (*single asterisk*) and *p* ≤ 0.0001 (*triple asterisk*). "Final" is the last observation carried forward. *LCIG* levodopa--carbidopa intestinal gel, *UPDRS* Unified Parkinson's Disease Rating Scale

Patients receiving LCIG experienced significant improvements from baseline in motor symptoms at all time points, as measured by UPDRS Part III total score (*p* \< 0.0001 at all time points, Fig. [3](#Fig3){ref-type="fig"}a). The largest improvement from baseline was seen after 3 months of treatment \[mean (SD) change from baseline of −12.9 (16.2)\]; improvements from baseline were around −9 thereafter. Patients receiving LCIG had a significant mean decrease from baseline in the PDQ-8 summary index score at all time points (*p* \< 0.0001 at month 3 and 6; *p* \< 0.001 at month 12 and final; Fig. [3](#Fig3){ref-type="fig"}b). The mean change in the NMSS total score from baseline was significant at every time point in patients receiving LCIG (*p* \< 0.0001), indicating that the significant improvement in non-motor symptoms was sustained over time (Fig. [3](#Fig3){ref-type="fig"}c). Patients manifested significant improvements in the mean change from baseline at every study visit in five of the nine NMSS domains: sleep/fatigue, mood/cognition, gastrointestinal tract, urinary, and miscellaneous (Table [2](#Tab2){ref-type="table"}).Fig. 3Mean (SD) change from baseline in measures of **a** motor symptoms, **b** quality of life, and **c** non-motor symptoms in the LCIG treatment group. Motor symptoms were measured by UPDRS Part III total score during the best "on" time; quality of life was measured by PDQ-8 summary index score; non-motor symptoms were measured using the NMSS total score. Statistical significance compared with baseline is indicated at *p* ≤ 0.01 (*double asterisk*) and *p* ≤ 0.0001 (*triple asterisk*). "Final" is the last observation carried forward. *LCIG* levodopa--carbidopa intestinal gel, *NMSS* Non-Motor Symptom Scale, *PDQ*-*8* Parkinson's disease questionnaire, *UPDRS* Unified Parkinson's Disease Rating Scale Table 2Change from baseline in NMSS domain scores in the LCIG treatment groupNMSS domainVisit, mean (SD)Month 3\
(*n* = 44)Month 6\
(*n* = 40)Month 12\
(*n* = 38)Final\
(*n* = 40)Cardiovascular including falls−1.7 (4.3)^a^−0.8 (3.0)−0.8 (3.3)−0.7 (3.2)Sleep/fatigue−6.8 (8.7)^d^−5.9 (8.0)^d^−5.6 (8.9)^c^−5.4 (8.7)^c^Mood/cognition−7.8 (14.3)^c^−7.6 (13.5)^b^−8.8 (13.9)^c^−8.4 (13.7)^c^Perceptual problems/hallucinations−1.1 (4.1)−1.5 (4.2)^a^−2.0 (5.0)^a^−1.9 (4.9)^a^Attention/memory−2.1 (8.0)−1.3 (8.3)−1.8 (7.8)−1.9 (7.7)Gastrointestinal tract−5.7 (6.4)^d^−4.4 (6.7)^c^−3.8 (6.4)^c^−3.8 (6.3)^c^Urinary−7.4 (10.7)^d^−5.9 (10.5)^b^−5.9 (9.9)^c^−5.5 (9.9)^b^Sexual function−1.3 (6.4)−0.5 (5.7)−0.3 (7.2)−0.2 (7.0)Miscellaneous−5.7 (9.5)^c^−5.9 (8.4)^d^−4.9 (9.5)^b^−4.7 (9.3)^b^"Final" represents the last observation carried forward*LCIG* levodopa--carbidopa intestinal gel, *NMSS* Non-Motor Symptom Scale, *SD* standard deviation^a^ *p* \< 0.05^b^ *p* \< 0.01^c^ *p* \< 0.001^d^ *p* \< 0.0001

### Standard-of-Care Treatment Group {#Sec13}

Patients in the standard-of-care group demonstrated small improvements from baseline of −1.5 (2.3) in UPDRS Part II total score at month 6, although the mean change from baseline at month 12 of 0.5 (5.3) indicates that there was no improvement from baseline at month 12 in the standard-of-care group (Supplemental Fig. 1A). Patients in the standard-of-care group also experienced some improvement from baseline in UPDRS Part III total score at months 3, 6, and at the final measurement (Supplemental Fig. 1B). Patients in the standard-of-care group experienced reductions from baseline in PDQ-8 summary index scores and numerical/formal improvements from baseline in non-motor symptoms at all time points (Supplemental Fig. 1C, D). Patients experienced improvements at each visit in four of nine NMSS subdomains: cardiovascular, mood/cognition, gastrointestinal, and miscellaneous (Supplemental Table 3). The small number of patients in the standard-of-care group did not allow for any statistical analyses.

Safety {#Sec14}
------

One-third of the patients (32.8%) experienced an AE. Eight patients (12.7%) experienced AEs that were considered to be possibly related to LCIG, as rated by the study investigator. Adverse events occurring in two or more patients included stoma site infection (4.7%), therapy cessation (4.7%), and psychotic disorder (3.1%). Of the 14 patients (21.9%) who experienced a serious AE, two patients (3.1%) experienced a psychotic disorder. Two patients (3.1%) experienced serious AEs reported by the study investigator to have a reasonable possibility of being related to the treatment: one patient had dopamine dysregulation syndrome, overdosed on orally administered levodopa/entacapone, suffered psychosis, and was hospitalized; the other patient had a mild lung infection and severe dystonia of both legs. Two patients (3.1%) died during the study (causes of death: cardiac failure and sudden death); both deaths were deemed by the investigator as having no reasonable possibility of being related to LCIG. Seven patients (11.1%) discontinued LCIG treatment because of AEs, including one of each of the following AEs: peristomal fasciitis, peritonitis, gastrostomy tube infection, dopaminergic dysregulation syndrome, severe dystonia, lack of clinical improvement, and a severed tube. Three AEs (stoma site infection, peristomal granuloma and gastric secretion, and peristomal fasciitis) were associated with three different product complaints and were reported in one patient each.

Discussion {#Sec15}
==========

Results from this prospective, multicenter, observational study showed significant improvements in activities of daily living, motor and non-motor symptoms, and quality-of-life scores, with safety results in accord with the known safety profile of LCIG \[[@CR11], [@CR12], [@CR17]\]. These results extend current findings, which have focused primarily on the effect of LCIG on motor complications \[[@CR10]--[@CR12], [@CR14]\]. As it has recently been suggested that there is a relationship between improvements in motor UPDRS and NMSS scores \[[@CR18]\], assessing the effect of both motor and non-motor symptoms on quality of life will be a boon to patients with advanced PD.

General disease progression and gradual deterioration of activities of daily living have been reported to occur at an average yearly decline in UPDRS Part II scores of 0.56 (measured during "on" time) \[[@CR19]\]. In the current study, LCIG treatment led to significant improvements in patients' activities of daily living from baseline to the final visit (primary endpoint), and at 3 and 6 months after starting LCIG therapy. The minimal clinically important difference in UPDRS part II scores has been previously determined to be 1.8 \[[@CR15]\]; results from the current study indicated improvements of 1.8 or more as observed at all time points. Patients treated with LCIG also experienced significant improvements from baseline in motor symptoms at each time point. The greatest improvement in UPDRS Part III scores was −12.9 at month 3; improvements in motor skills were sustained around −9 for the remainder of the study. The minimal clinically important difference in UPDRS part III scores has been previously reported to be 2.5 points, with moderate improvement classified as 5.2 points, and large improvement at 10.8 points \[[@CR20]\]. On the basis of these criteria, patients in this study experienced moderate-to-large clinically important improvements in motor symptoms.

Non-motor symptoms have been shown to negatively impact quality of life in both patients and caregivers \[[@CR4], [@CR6]--[@CR8], [@CR21]\]. However, non-motor symptoms are frequently not well recognized and assessed in clinical practice \[[@CR22]\]. In this study, patients treated with LCIG experienced significant improvements from baseline in non-motor symptoms, with corresponding improvements in quality of life (as measured by PDQ-8), at all time points. Overall improvements from baseline in quality of life and non-motor symptoms were similar to those reported in other observational, routine-care studies \[[@CR23], [@CR24]\]. Patients experienced significant improvements from baseline for sleep/fatigue, mood/cognition, gastrointestinal tract, urinary, and miscellaneous NMSS subscores. LCIG treatment has previously demonstrated a varied degree of significant improvement in these same subdomains in other studies \[[@CR6], [@CR23]--[@CR25]\]. When compared with results in other studies assessing non-motor symptoms in patients receiving LCIG, patients in the current study exhibited greater improvements in mood/cognition, less improvement in sleep/fatigue, and improvements in gastrointestinal and urinary symptoms in between the improvements seen in other studies \[[@CR6], [@CR23]\]. Patients treated with DBS have demonstrated significant improvement in NMSS total score and six of nine subdomains, although improvements in these patients were generally of smaller magnitude than in the current study (except for sleep/fatigue) \[[@CR26]\], which may account for the larger improvements in quality of life experienced by patients undergoing LCIG treatment. Treatment with apomorphine infusion has also demonstrated significant improvements in NMSS total score and in six of nine subdomains; improvements in urinary function were not to the same degree as noted in the current study \[[@CR24]\]. Among the variety of non-motor symptoms observed in PD patients, it was recently shown that mood was consistently among the most important predictors for an impact on quality of life \[[@CR21], [@CR27], [@CR28]\], which further underscores the relevance of the observed greater improvement in mood/cognition in the present study.

Individuals in the standard-of-care treatment group did show some numerical/formal and/or transient improvements from baseline in activities of daily living, quality of life, and non-motor symptoms. However, the size of the standard-of-care group was small, and the size fluctuated over the course of the study, as patients could switch to the standard-of-care group at any time during the study. Consequently, patients who may have initially been treated with LCIG before switching to the standard of care may have altered the outcomes in the standard-of-care group. Further, the variability and small size of the standard-of-care group precluded any statistical analyses and any comparisons between groups.

The safety results were consistent with the established safety profile of LCIG \[[@CR11], [@CR12], [@CR17]\]; no new safety concerns were reported or detected. The most common AEs were related to maintenance of the stoma site. It has been reported that there is considerable potential for gastrointestinal serious adverse events with LCIG treatment \[[@CR29]\]; however, in this study, there was only one incident of peritonitis, and all gastrointestinal serious adverse events were not considered to be related to the treatment. In addition, axonal neuropathy has been reported in patients treated with LCIG \[[@CR30]\]; however, there were no reports of neuropathy in the current study. Although there was a relatively high (35.9%) overall rate of discontinuation from LCIG treatment, in only 11.1% of patients it was due to AEs.

Interestingly, patients in this study tended to be older (mean age of 70.4 vs. 64 years) and have a longer disease duration (mean duration of 14 vs. 12.5 years) than patients in a previous open-label study, despite similar inclusion criteria \[[@CR11]\]. Moreover, the magnitude of improvement of activities of daily living (as assessed by UPDRS II) was smaller than previously reported (−2.1 vs. −4.4). The observed older age of patients included in the present study could have an impact on the treatment response and benefit, as it has been shown for other interventional therapies \[[@CR31], [@CR32]\].

A limitation of this study design is that the effectiveness measures were based on self-reported assessments and did not include a diary to assess motor benefit. Because this study was conducted as an observation of routine care with LCIG, these outcomes are considered to be close to what may be observed in real-world clinical practice. Nonetheless, this study was limited by the observational design and the lack of a true control group. Because patients in the standard-of-care group could have initiated LCIG before they decided to transition back to standard-of-care treatment (and also back to LCIG), no direct comparisons or statistical analyses can be made between the groups. Further prospective randomized controlled studies are needed to assess the differences between LCIG and standard of care in activities of daily living, non-motor symptoms, and quality of life.

Conclusion {#Sec16}
==========

This study demonstrated significant and clinically relevant improvements in measures of activities of daily living, motor and non-motor symptoms, and quality of life after treatment with LCIG. Despite a relatively high rate of discontinuation, these data indicate that in addition to the previously reported safety and efficacy, LCIG also provides significant benefits to activities of daily living, non-motor symptoms, and quality of life in patients with advanced PD.
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